Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium oxybate for idiopathic hypersomnia
2017-004122-15Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypersomnolence disorder comparing Sodium oxybate with Placebo (2 arms). Primary endpoints: Epworth Sleepiness Scale (ESS) score at endpoint and Multiple Wakefulness Test (MWT) latency at 8 weeks. Started Jun 2018; status: completed.
02
Drugs
sodium oxybate
03
Conditions
hypersomnolence disorder
Beyond the preview
Go deeper on 2017-004122-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004122-15.